ストックスクリーナーアプリを入手
13.70
3.86%
-0.55
前日終値:
$14.25
開ける：
$14.25
24時間の取引高:
179.22K
Relative Volume:
0.88
時価総額：
$398.37M
収益：
$69.21M
当期純損益:
$-61.98M
株価収益率:
-5.28
EPS:
-2.5947
ネットキャッシュフロー:
$-9.61M
1週間 パフォーマンス:
-9.33%
1か月 パフォーマンス:
+17.09%
6か月 パフォーマンス:
+4.50%
1年 パフォーマンス:
+96.28%
1日の値動き範囲:
$13.24
$14.47
1週間の範囲:
$13.24
$15.10
52週間の値動き範囲:
$6.435
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
名前
Enanta Pharmaceuticals Inc
セクター
電話
617 607 0800
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
13.70 | 398.37M | 69.21M | -61.98M | -9.61M | -2.5947 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Rodman & Renshaw | Buy |
| 2025-11-14 | 開始されました | JP Morgan | Overweight |
| 2025-10-01 | アップグレード | Jefferies | Hold → Buy |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2023-08-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-08-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 開始されました | Evercore ISI | Underperform |
| 2020-08-28 | 再開されました | ROTH Capital | Buy |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-07-27 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 開始されました | Wolfe Research | Outperform |
| 2019-04-23 | アップグレード | Berenberg | Hold → Buy |
| 2018-12-13 | 開始されました | Berenberg | Hold |
| 2018-06-06 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-07-11 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | Barclays | Underweight |
| 2015-10-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2015-10-23 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
すべてを表示
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP - TradingView
Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st - ad-hoc-news.de
Enanta Pharmaceuticals (ENTA) Rebounds 2.3% as Shares Approach Key Resistance ZoneUnusual Call Volume - dars.gov.et
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering - TipRanks
Enanta Enters $75 Million At-the-Market Stock Offering Agreement - Moomoo
Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Enanta Pharmaceuticals (ENTA) Rallies 4%: Key Support and Resistance Levels in FocusAggressive Growth Picks - dars.gov.et
AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret - MSN
Enanta Pharmaceuticals (ENTA) moves 5.2% higher: Will this strength last? - MSN
Enanta Pharmaceuticals sets out pipeline catalysts, shares watched by biotech investors - AD HOC NEWS
Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA) - TradingView
Pfizer patent win against Enanta over COVID pill upheld by appeals court - MSN
Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
ENTA Forecast — Price Target — Prediction for 2027 - TradingView
PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
EC approves label expansion for Enanta’s Maviret in acute HCV infection - The Pharma Letter
Form 8K Enanta Pharmaceuticals Inc For: 23 June - Investing.com UK
Federal appeals court upholds invalidity of Enanta patent in Pfizer case By Investing.com - Investing.com South Africa
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com South Africa
Federal appeals court upholds invalidity of Enanta patent in Pfizer case - Investing.com UK
H.C. Wainwright reiterates Enanta stock rating on FDA alignment - Investing.com UK
Enanta Faces Patent Setback in Paxlovid Litigation - TipRanks
H.C. Wainwright reiterates Enanta stock rating on FDA alignment By Investing.com - Investing.com South Africa
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan
CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application - IPWatchdog.com
Fed. Circ. Backs Pfizer Win In Paxlovid Patent Dispute - Law360
Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral - Bloomberg Law News
Enanta (ENTA) Secures EU Approval for Maviret Treatment - GuruFocus
ENTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace
Enanta Pharmaceuticals Inc (ENTA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):